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Introduction:  In vivo 31P Magnetic  Resonance  Spectroscopy  (MRS)  measures  phosphorus-containing
metabolites  that  play  an  essential  role  in  many  disease  processes.  An  advantage  over 1H MRS  is  that
total choline  can  be separated  into  phosphocholine  and  glycerophosphocholine  which  have  opposite
associations  with  tumour  grade.  We  demonstrate 31P  MRS can provide  robust  metabolic  information  on
an acceptable  timescale  to  yield  information  of  clinical  importance.
Methods:  All  MRI  examinations  were  carried  out  on  a 3T whole  body  scanner  with  all 31P  MRS  scans
conducted  using  a dual-tuned 1H/31P  head  coil.  Once  optimised  on  phantoms,  the  protocol  was  tested  in
six  healthy  volunteers  (four  male  and  two  female,  mean  age:  25 ±  2.7). 31P  MRS  was  then  implemented
on  three  children  with  optic  pathway  gliomas.
Results: 31P  MRS  on volunteers  showed  that  a number  of  metabolite  ratios  varied  signiﬁcantly  (p  <  0.05
ANOVA)  across  different  structures  of the  brain,  whereas  PC/GPC  did  not.  Standard  imaging  showed  the
optic  pathway  gliomas  were  enhancing  on  T1-weighted  imaging  after  contrast  injection  and  have  high
1 31tCho on H  MRS,  both  of  which  are  associated  with  high  grade  lesions. P MRS  showed  the  phospho-
choline/glycerophosphocholine  ratio  to be low  (<0.6)  which  suggests  low  grade  tumours  in keeping  with
their clinical  behaviour  and  the  histology  of  most  biopsied  optic  pathway  gliomas.
Conclusion: 31P  MRS  can  be implemented  in  the  brain  as  part  of  a clinical  protocol  to provide  robust
measurement  of  important  metabolites,  in  particular  providing  a greater  understanding  of  cases  where
tCho  is raised  on 1H  MRS.
© 2013 Published by Elsevier Ireland Ltd.. Introduction
In vivo Magnetic Resonance Spectroscopy (MRS) is able to pro-
le the chemical composition of deﬁned regions of interest in
he brain. The 1H nucleus is the most commonly probed due to
ts high gyromagnetic ratio and widespread development of both
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ttp://dx.doi.org/10.1016/j.ejrad.2013.11.009hardware and techniques. While the use of 1H MRS  is now becom-
ing more prevalent for brain tumour diagnosis and assessment of
treatment efﬁcacy, it can be difﬁcult to implement across some
important regions of the brain and cannot reliably quantify a num-
ber of metabolites of clinical and biological importance [1]. 31P MRS
can measure a number of these key metabolites, does not suffer
from problems of water and fat contamination and requires a less
homogeneous magnetic ﬁeld. Prior to the development of water
suppression, 31P was  the nucleus of choice for investigating in vivo
metabolic activity but has since suffered from a lack of technical
development and integration into clinical MRI  systems. 31P MRS
may  seem unattractive due to the low SNR which leads to poor spa-
tial resolution (large voxel sizes) and importantly long acquisition
times [2]. Other barriers to its widespread use are the require-
ment of a dedicated 31P coil and the lack of advanced processing
software available for automated quantiﬁcation of the metabolites.
However, technical advances are making 31P MRS  a viable option
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Fig. 1. It was found that increasing the TR gave a greater improve-
ment in the SNR than would have been achieved by increasing
the number of averages for the same total acquisition time. It was
decided that a TR of 4000 provided an appropriate level of SNR andJ. Novak et al. / European Journal o
linically and it is now appropriate to develop and evaluate proto-
ols suitable for clinical practice and use them to investigate brain
etabolism.
Higher ﬁeld scanners provide increased SNR [3], reducing
can times, dedicated head coils have recently become available,
roviding complete brain coverage [4] and the advent of 1H-
ecoupled 31P MRS  has increased the spectral resolution allowing
hosphomonoesters (PME) and phosphodiesters (PDE) to be decon-
oluted into their constituent resonances. Phosphocholine (PC),
lycerophosphocholine (GPC), glycerophosphoethanolamine (GPE)
nd phosphoethanolamine (PE) can be separately identiﬁed over-
oming a limitation of clinical 1H MRS  which can only detect a
Cho peak, which is a linear combination of these metabolites.
n tumours, it is well established that the biomarker roles of PC
nd GPC are different and this could account for the conﬂicting
esults of studies on the relationship between tCho and tumour
ggressiveness [5]. A recent study has shown the importance of
C and GPC levels in differentiating Grade II and IV Astrocytomas
sing ex vivo MRS  in adults [6] where elevated levels of PC were
ound in the Grade IV lesions and high GPC was found in the Grade
I lesions. There is also evidence that the ratio PC/GPC could be
 useful biomarker of tumour response [7]. One clinical scenario
here this technique could be particularly important is paediatric
ptic pathway gliomas. These are often large, unresectable tumours
hich are enhancing with a high tCho peak. Ordinarily, this would
e indicative of a high grade aggressive tumour but if biopsied they
re commonly diagnosed as grade I pilocytic astrocytomas. These
umours present major challenges for clinical management since
heir behaviour is varied and cannot be predicted by conventional
echniques. A non-invasive tool for accurate diagnosis, prognosis
nd monitoring would be a major advance. It is hypothesised that
econvolution of the high tCho peak could provide further under-
tanding of the biology of these tumours and yield important new
iomarkers. 31P MRS  has other potential uses including evalua-
ion of high-energy phosphates, adenosine-triphosphate (ATP) and
denosine diphosphate (ADP) and measures the pH of a system
sing relative shift of measured peaks [8]. The development of a 31P
RS  method which provides information on the key phosphorous-
ontaining metabolites on a clinically applicable timescale from any
egion in the head would be a major step forward in the implemen-
ation of the technique as a tool for radiologists.
In this study we develop a 31P MRS  protocol in phantoms
nd volunteers and then adapt it to the investigation of regional
etabolite variability across the brain in healthy adult volunteers
nd to paediatric patients with unbiopsied optic pathway glioma.
uantiﬁcation of the spectra is facilitated by a new adaptation of
he fully automated TARQUIN algorithm [9] to 31P MRS.
. Materials and methods
.1. Phantom design
A phantom was designed to assess the signal-to-noise ratio,
ecoupling and localisation efﬁciency of 31P MRS. This consisted
f a cylindrical plastic container in which the bottom half was
lled with a 1% (w/w) agarose gel (Invitrogen Life Technologies)
ith 5 mM  sodium phosphate (Sigma Aldrich). This layer was then
ealed with a non-permeable polymer ﬁlm. Once solidiﬁed, another
ayer of 1% agarose gel was poured on top, this time with 5 mM
hosphoethanolamine (Sigma Aldrich)..2. MR  acquisition
All data were acquired on a Philips Achieva 3 T TX system (Best,
etherlands). Volunteer and phantom scans were conducted solelyology 83 (2014) e106– e112 e107
using a dual-tuned 31P/1H head coil (Rapid Biomedical, Germany).
Parameters for the ﬁnal acquisition protocol used in patients were
optimised using a combination of phantoms and volunteers.
Patient data were acquired using a combination of both the
31P/1H head coil and a 32 channel 1H Philips head coil. Standard
imaging was  performed using the 32 channel 1H head coil or the
neurovascular coil. Basic localiser imaging and 31P spectroscopy
was  performed using the 31P/1H head coil.
2.3. Phantom experiments
A three plane T1-weighted localiser imaging sequence was used
for spectroscopic volume positioning. Prior to the acquisition of 31P
spectra, a single slice 10 mm thick T1-weighted image was acquired
in the same orientation as the 31P MRS  acquisition to enable accu-
rate positioning and post-experimental analysis.
2.4. Protocol optimisation on volunteers
Further optimisation of parameters was conducted using volun-
teers. Voxels were 30 mm × 30 mm  with a slice thickness of 30 mm
resulting in a volume of 27 cm3. Improved SNR and equivalent shim
was  observed for 35 mm  × 35 mm voxels which were employed in
patients when tumours were sufﬁciently large. The echo time was
the shortest possible at 0.31 ms.  To ensure optimal spatial local-
isation using the ISIS technique, eight averages were acquired. The
bandwidth was 3000 Hz with 1024 spectral points collected.
The repetition time was  optimised via a series of scans which
were conducted on the white/grey matter of volunteers at four
different TRs. Representative data from these scans are shown inFig. 1. A series of 31P MR  spectra acquired from a mixture of white and grey matter
with different repetition times (TRs). The feint lines represent the raw data and the
dark line represents the ﬁt. (a) TR = 4000 ms, (b) TR = 3000 ms,  (c) TR = 2000 ms and
(d) TR = 1000 ms.
e108 J. Novak et al. / European Journal of Radiology 83 (2014) e106– e112
Fig. 2. Representative 31P Magnetic Resonance Spectroscopic Imaging (MRSI) spec-
trum obtained from a healthy volunteer. The orientation of the pseudo axial image
shown on the left is the same orientation as the MRSI grid shown on the right hand
side. The orientation of the MRSI grid allowed simultaneous metabolic proﬁling of
various regions of the brain: the cerebellum (voxel 4), the brain stem (voxel 3), the
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Table 1
Showing the ﬁnalised 31P protocol for both the volunteer study and the protocol
used for the patients.
Parameter Volunteer study Patient protocol
Localisation MRSI (ISIS) MRSI (ISIS)
k-Space mask Elliptical (80%) Elliptical (80%)
TR/ms 4000 3000–4000
TE/ms 0.31 0.31
Number of averages 8 8
Voxel size/mm 30 × 30 ≤35 × 35
Slice thickness/mm 30 30
Matrix size 7 × 7 ≥6 × 5
Bandwidth/Hz 3000 3000
Data points acquired 1024 1024asal ganglia (voxel 2) and the white/grey matter of the frontal lobe (voxel 1). The
epresentative 31P spectrum was obtained from the brain stem.
till would be able to measure signals from the choline-containing
etabolites in less cellular tumours which may  have lower concen-
rations. TRs < 4000 resulted in insufﬁcient SNR and TRs < 3000 ms
ntroduced T1 saturation effects.
.5. Volunteer studies using the optimised protocol
Six healthy volunteers (four male and two female) were studied
ith a mean age of 25 ± 2.7 in full compliance with our research
thics.
Fig. 2 shows the positioning of the MRSI grid used to acquire
he 31P spectra in volunteers. The regions actively targeted for this
tudy were the basal ganglia, which is mainly grey matter and is
f particular interest for inherited metabolic disorders [10], the
rontal lobe which contains a mixture of white and grey matter, the
rain stem and the cerebellum. A single MRSI slice was sufﬁcient
o capture all of the aforementioned regions, although all voxels
ontained multiple tissue types due to the large size. The 31P MRS
cquisition time for the volunteer study was 20 min  using a MRSI
rid size of 7 × 7. The 31P MRS  parameters for both the volunteer
tudy and the proposed protocol for patients are summarised in
able 1.
.6. Patient acquisitions
Three patients (two male and one female, age = 2.7 ± 1.5
ears) with unbiopsied, optic pathway gliomas were investigated.
nformed parental consent was obtained prior to the 31P MRS  exam-
nation which was conducted after essential clinical imaging. Post
linical imaging, the 1H head coil was removed from the scanner
nd replaced with the dual-tuned 1H/31P head coil. 31P scanningAcquisition time/min 20 6–12
time varied between patients, with the longest time 12 min  and
the shortest 6 min.
Single voxel 1H spectra (SVS) were acquired using the Point
REsolved SpectroScopy (PRESS) technique employing a short echo
time (37–40 ms). The voxels were 2 cm × 2 cm × 2 cm (8 cm3 vol-
ume) for all of the cases. A repetition time of 2000 ms  was
used with 96–128 averages acquired. The bandwidth was  2000 Hz
with 1024 data points acquired with a total scanning time of
6 min.
2.7. Processing and analysis
All data were exported from the scanner in DICOM format and
subsequently processed by version 4.2.6 of the TARQUIN algorithm
[9] for the volunteers, version 4.2.9 was used for phantoms and
version 4.2.10 was used for patients. These versions of TARQUIN
have been adapted speciﬁcally to allow analysis of 31P MRSI data
with the latter versions allowing manual phasing and peak ref-
erencing which is ideal for phantom studies. The 31P spectra for
volunteers were automatically processed by TARQUIN including
Fourier transformation, zeroth and ﬁrst order phasing and ﬁtted
using a simulated 31P brain basis set. Prior to ﬁtting, all spectra
were referenced to PCr which was set to 0 PPM on the chemical
shift scale.
New basis sets were optimised for both the volunteers and the
brain tumour patients. The following metabolites were simulated
using a single Lorentzian peak PE, PC, PI(tissue) (inorganic phosphate
in the tissue), GPE, GPC, PCr, and NADH. ATP was simulated using
two  of the 3 resonances:  and  peaks which were both doublets
with a j-coupling of 16 Hz. -ATP was excluded from the basis set
due to phasing issues. Despite being a superposition of ATP and ADP
peaks, the resonances will be referred to only as ATP. Two  additional
peaks were included in the basis set for the brain tumour patients
which were: PI(blood), which is inorganic phosphate found in the
blood and a peak at 2.2 PPM which has been previously attributed
to phosphoenol pyruvate (PEP) [11].
All spectra were assessed by an experienced spectroscopist and
quality assessment was  applied to the spectroscopy. All of the 31P
data passed QA apart from one spectrum in the frontal lobe.
The absolute quantiﬁcation of metabolites measured using 31P
spectroscopy is challenging due to the lack of water reference which
can be used as a denominator. No corrections have been made
for the different 31P T1 values for metabolites within the brain
due to the long times associated with accurate T1 measurements.
Multiple TR scans indicated that major differences did not exist
between the T1 values of the different metabolites. No corrections
were made for different T2 values for various metabolites mea-
sured by 31P experiments or for the NOE enhancement of separate
resonances.
J. Novak et al. / European Journal of Radiology 83 (2014) e106– e112 e109
Fig. 3. (a) Shows a localiser image in an axial orientation of a gel phantom ﬁlled
with 1% agar. Voxels 1 and 2 are placed over the gel containing inorganic phosphate
(PI) and voxels 3 and 4 were placed over gel containing phosphoethanolamine (PE).
Spectra 1–4 correspond to the voxels in the image with the elliptical k-space mask
on  in (i) and off in (ii). The peak at 0 ppm corresponds to PE and the peak at 2 ppm
corresponds to PI. (b) Shows the effect of decoupling on the PE resonance in the gel
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Fig. 4. Showing the positioning of a 2 cm × 2 cm × 2 cm single-voxel 1H Magnetic
brain tumours. The presence of both lipids and lactate is consistenthantom. The thicker line shows the PE resonance with decoupling and the thinner
ine is without decoupling.
.8. Statistics
All statistical calculations were conducted using the program
, version 2.15.0 (the R foundation for Statistical Computing). For
he ratios, the variance was analysed using an ANOVA test across
he four different regions of the brain. If the ANOVA test revealed a
tatistical difference (p < 0.05) a Tukey’s signiﬁcant difference test
as performed to allow for multiple comparisons.
. Results
.1. Phantom optimisation
The images for the phantom and spectra showing both local-
sation and decoupling for the phantoms are shown in Fig. 3. 31P
pectra were acquired using a 2D Magnetic Resonance Spectro-
copic Imaging (MRSI) technique employing Image Selected In vivo
pectroscopy (ISIS) localisation. The data acquired for the localisa-
ion efﬁciency is shown in Fig. 3(a). The effect of an elliptical mask,
hich samples 80% of k-space, therefore reducing the acquisition
ime, was investigated using the gel phantom described above and
s also demonstrated in Fig. 3(a). An inter-voxel signal contamina-
ion of 7–11% in the absence of the ﬁlter and 18–25% with the ﬁlter
as found.
Broadband decoupling was carried out using the 1H channel of
he dual tuned coil using a WALTZ4 technique with a frequency
ffset of −100 Hz. The decoupling duration was limited to 237.2 ms
nstead of the optimal 347.7 ms  because of hardware constraints.
his did not visibly affect decoupling efﬁciency due to the short
2 values of the 31P nuclei which result in a rapid signal decay.
hantom data in Fig. 3(b) shows the decoupling was  able to resolve
he PE resonance from a triplet to a singlet, effectively reducing the
ine width of the PE peak from 19 to 9 Hz. The decoupling efﬁciencyResonance Spectroscopy (MRS) acquisition of an unbiopsied optic pathway glioma
and below it the 1H MR  spectrum acquired. The lighter line in the 1H MR spectrum
is  the data and the solid black line is the ﬁt from the TARQUIN software.
was  also evaluated in volunteers showing clearly resolved peaks
for PE, PC, GPE and GPC.
Narrowband NOE enhancement was  used to further increase
the SNR using an offset of −100 Hz and a mix time of 3500 ms  and a
B1 max  of 0.3 T. Phantom measurements showed that the signal
intensity was increased by 6% for PE and 5% for inorganic phosphate.
3.2. Volunteer metabolite ratios
The collated ratio data from all regions of the brain for 31P
metabolites are shown in Table 2 which indicated metabolite ratios
vary throughout the brain. A signiﬁcantly lower PCr/ATP ratio was
found in the basal ganglia when compared to both the brain stem
(p < 0.05) and the cerebellum (p < 0.005). PCr/ATP was  signiﬁcantly
higher in both the brain stem and the cerebellum compared with
the frontal lobe (both p < 0.05). GPE/ATP ratio was found to be
higher in the brain stem than in the basal ganglia (p < 0.05). Signiﬁ-
cantly higher PE/GPE was  found in both the basal ganglia (p < 0.05)
and the frontal lobe (p < 0.05) compared to the brain stem. Lower
values for PE/PCr were found in the brain stem compared to the
basal ganglia (p < 0.05) and the frontal lobe (p < 0.01). Lower PE/PCr
was  also found when spectra from the cerebellum were compared
to both the basal ganglia (p < 0.05) and the frontal lobe (p < 0.005).
There was no signiﬁcant difference detected in the PC/GPC ratio
across the brain regions evaluated. The study would have had 80%
power to have detected a difference of 0.16 in the PC/GPC ratio with
a conﬁdence level of 5% (2 tailed T-test).
3.3. Patient data
A representative 1H MRS  PRESS single voxel spectrum acquired
from a paediatric optic pathway glioma is shown in Fig. 4. The
important feature of this spectrum is the exceptionally high tCho
relative to the other metabolites in the spectrum. The tNAA is rela-
tively low, indicating low neuronal density which is consistent withwith brain lesions and is not ordinarily found in healthy brain tissue.
A 31P MRSI spectrum of the same paediatric optic pathway
glioma is shown in Fig. 5 along with the MRSI grid positioning.
e110 J. Novak et al. / European Journal of Radiology 83 (2014) e106– e112
Table 2
Showing collated data from the volunteers. The data are reported as the mean ± the standard deviation.
Metabolites Brain stem Cerebellum Basal ganglia Frontal lobe ANOVA test p
PE/ATP 0.56 ± 0.05 0.56 ± 0.05 0.59 ± 0.11 0.63 ± 0.10 0.429
GPE/ATP 0.51 ± 0.07 0.43 ± 0.06 0.39 ± 0.08 0.42 ± 0.08 0.047*
PC/ATP 0.23 ± 0.04 0.22 ± 0.05 0.16 ± 0.07 0.14 ± 0.14 0.211
GPC/ATP 0.66 ± 0.09 0.58 ± 0.10 0.56 ± 0.12 0.61 ± 0.10 0.453
PI/ATP 0.46 ± 0.11 0.41 ± 0.05 0.40 ± 0.09 0.45 ± 0.09 0.473
PCr/ATP 1.72 ± 0.16 1.80 ± 0.20 1.34 ± 0.11 1.38 ± 0.30 0.001*
NADH/ATP 0.25 ± 0.05 0.26 ± 0.10 0.23 ± 0.10 0.38 ± 0.09 0.062
PE/GPE 1.11 ± 0.17 1.32 ± 0.22 1.55 ± 0.33 1.53 ± 0.15 0.013*
PC/GPC 0.35 ± 0.05 0.39 ± 0.10 0.28 ± 0.12 0.25 ± 0.25 0.380
PC/PE  0.40 ± 0.06 0.40 ± 0.08 0.27 ± 0.13 0.23 ± 0.23 0.118
PE/PCr 0.33 ± 0.02 0.31 ± 0.03 
* Indicates a signiﬁcant difference was present (p < 0.05).
Fig. 5. Showing a 31P Magnetic Resonance Spectroscopic Imaging (MRSI) acquisition
of  a paediatric patient with an unbiopsied optic pathway glioma. The displayed
spectrum was obtained from the voxel highlighted in red. (For interpretation of the
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meferences to colour in this ﬁgure legend, the reader is referred to the web  version
f  the article.)
he quality of the spectra was good and importantly the spectral
eparation of the choline-containing peaks was even better than
bserved in healthy volunteers. The PCr peak was lower than was
bserved for the volunteers which is consistent with the 1H spec-
roscopy where total creatine was low compared to healthy brain.
he PI peak is no longer represented by a single peak but has split
nto two resonances. The upﬁeld peak (PI(tissue)) is consistent with
rain tissue (pH calculated as ≈7) and the downﬁeld peak(PI(blood))
onsistent with blood where the pH is calculated as ≈7.35.
able 3
howing metabolite ratios for both the tumours and healthy tissue of three paediatric pa
ean  of voxels with normal appearing brain on conventional MRI included in the MRSI g
Metabolites Patient 1 Patient 
Normal Tumour Normal
PC/GPC 0.60 ± 0.18 0.41 0.48 ± 
GPE/ATP 0.31 ± 0.05 0.22 0.25 ± 
PC/ATP 0.25 ± 0.05 0.19 0.21 ± 
GPC/ATP 0.45 ± 0.15 0.47 0.45 ± 
PI/ATP 0.23 ± 0.08 0.24 0.30 ± 
PCr/ATP 1.20 ± 0.04 0.82 1.00 ± 
NADH/ATP 0.38 ± 0.04 0.42 0.33 ± 
PE/GPE 2.04 ± 0.54 2.52 2.59 ± 
PC/PE  0.40 ± 0.04 0.36 0.34 ± 
PE/PCr 0.52 ± 0.04 0.66 0.63 ± 0.44 ± 0.07 0.47 ± 0.11 0.0009*
Signiﬁcant PEP levels were observed in one patient. The PC/GPC
ratio is low across all of the patients and all other metabolite ratios
are shown in Table 3. The table also includes internal control ratios
from the patients where uninvolved brain is included in the MRSI
grid. This data was  derived from an average of voxels which do
not include tumour on the conventional MRI  and were chosen
for both spectral quality and distance from the lesion. An average
from different anatomical regions was used since the volunteer
data showed that there was no statistical difference present for
PC/GPC across different brain regions (at least in young adults). We
were unable to use purely contralateral voxels as the tumours are
positioned in the midline of the brain or affect both hemispheres.
4. Discussion
A 31P MRS  imaging protocol has been developed using a dedi-
cated head coil and implemented in volunteers to obtain metabolite
values across a range of different tissues in the brain. The method
was  straightforward to implement and produced good quality
data in all volunteers, despite selecting a challenging volume of
interest which included the cerebellum, brain stem, basal ganglia
and frontal cortex. Data acquisition was  combined with a new
technique for the automated quantiﬁcation of metabolite levels
in 31P MRS  to provide a straightforward method for obtaining
ratios of phosphorous-containing metabolites. Metabolite ratios
were quantiﬁed accurately enough to observe signiﬁcant variations
between different regions of the brain. The protocol can be adapted
to be used on a clinically viable timescale without any detrimental
effect on the quality of the data, which is crucial if it is to be used
on patients.
Variation in the concentration of metabolites within different
regions of the brain has been studied previously using H MRS
[12] which indicated that metabolites are not homogeneously dis-
tributed across all structures within the brain. A study by Buchli
et al. compared 31P-measured metabolites in cortical brain and the
tients with optic pathway gliomas. The normal data for each patient represent the
rid. The ± value is the standard deviation.
2 Patient 3
 Tumour Normal Tumour
0.17 0.34 0.49 ± 0.12 0.57
0.04 0.31 0.23 ± 0.00 0.14
0.07 0.20 0.17 ± 0.05 0.21
0.04 0.59 0.35 ± 0.04 0.38
0.07 0.31 0.25 ± 0.02 0.18
0.07 1.21 1.06 ± 0.07 0.71
0.02 0.35 0.34 ± 0.05 0.26
0.37 2.14 2.64 ± 0.17 4.50
0.11 0.30 0.28 ± 0.07 0.33
0.04 0.55 0.56 ± 0.03 0.91
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[J. Novak et al. / European Journal o
erebellum of healthy volunteers [13]. They showed there were
etabolite concentration differences between both the cerebrum
nd the cerebellum and also the deep white and cortical grey
atter. A paper studied metabolites in diseased and healthy mid-
rain and the putamen using 31P MRS  [14] but no comparisons
etween brain regions were made. To our knowledge, the variation
f metabolites across multiple structures in the brain within the
ame subject has not been systematically studied using 31P MRS.
hilst the number of volunteers in the study is relatively small, the
ariability between the subjects is sufﬁciently low that the most
mportant ﬁndings are likely to have been detected and be repro-
ucible. However, it would be worthwhile conﬁrming the ﬁndings
n a larger cohort which would also have the power to detect more
ubtle differences between brain regions.
Our experience is that the technique was easier to implement
nd more robust (supplementary ﬁgure) than 1H MRSI, where the
ollection of data across the investigated regions was very challeng-
ng. Methods previously used for quantiﬁcation of 31P MRS  include
hantom replacement [14] and in situ phantom calibration [15]
oth of which are impractical in a busy clinical environment. For
his study we used solely metabolite ratios, almost all of which
easured in the volunteers were within the reported errors of the
ontrol data from children published in the paper by Bluml et al.
16]. Their study did not employ a dual-tuned head coil with full
ead coverage and was conducted using a ﬁeld strength of 1.5 T. Our
se of a dedicated head coil allows the study of multiple regions of
he brain and utilising ﬁeld strength of 3 T affords greater SNR per
nit time. It is encouraging that we observe similar ratios to those
eported in the study by Bluml et al. despite the differences in the
cquisition protocol and the hardware used to acquire the data.
he only observed differences between the two  studies were in the
etabolite PE which can be explained by the relative ages of the
ontrols used by Bluml et al. and our volunteers. Our volunteers
ere signiﬁcantly older (25 ± 2.7) than the Bluml study (6.3 ± 5.3)
nd PE has been shown to signiﬁcantly decrease as a function of
ge [17].
Supplementary material related to this article can be found,
n the online version, at http://dx.doi.org/10.1016/j.ejrad.
013.11.009.
1H MRS  measurements for the optic pathway gliomas all show
igh total choline relative to the other metabolites. This phe-
omenon is counter intuitive when compared with the general
nding that high tCho is indicative of high malignancy [5]. The
Cho peak is composed mainly of PC and GPC and it has been
hown previously that the PC/GPC ratio is a better indicator of
umour aggressiveness with PC dominating in high grade tumours
ut GPC being high in those of low grade [16,18], although it is not
et certain which characteristics associated with malignancy the
C/GPC ratio best reﬂects particularly for paediatric tumours. When
ssessed with 31P MRS, we have shown that the majority of the tCho
eak is accounted for by GPC as opposed to PC, conﬁrming the low
rade nature of these tumours. We  do not believe that the PC/GPC
atio can be attributed to age related changes in these metabolites
s very little difference has been observed above one year of age
17]. There could be some contribution to the tCho peak from free
holine which would not be detected by 31P MRS but levels of this
etabolite are usually low in tumours and it has not been linked
o tumour grade [18]. There are also contributions to the tCho peak
rom PE and GPE but these are low due to the comparatively small
umber of protons contributing to the peak at 3.2 ppm (1 for PE
nd GPE and 9 for GPC and PC) and the J-coupling which effec-
ively reduces the peak height. The low PC/GPC ratio measured in
he optic pathway gliomas is consistent with the low grade nature
f these tumours and we believe is the only known non-invasive
iomarker which provides this information on this type of tumour.
he technique used is particularly pertinent to tumours which are
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located deep within the brain for which surgery poses a signiﬁcant
risk such as the cases presented here. These ﬁndings warrant the
study of a larger patient cohort to evaluate PC/GPC and other 31P
MRS  biomarkers in the diagnosis, prognosis and treatment efﬁcacy
monitoring of these tumours.
5. Conclusion
31P MRS  is easy to acquire with a dedicated head coil and
produces robust and reproducible results across a number of
important brain regions in a clinically applicable timescale. Dif-
ferences in metabolite ratios occur across healthy brain and need
further investigation. Metabolite levels in volunteers are consistent
with those previously reported, implying that 31P MRS  is repro-
ducible across different scanners. 31P MRS  in optic pathway gliomas
of childhood exhibiting, high tCho peaks in 1H MRS, showed that
GPC contributed more to this peak than PC. We  believe that the
PC/GPC ratio is the ﬁrst non-invasive biomarker showing these
tumours are low grade. 31P MRS  should be more extensively used
in the assessment of brain tumours and its optimum role in clinical
practice determined.
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